Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > MagForce Nanotechnologies AG Receives European Regulatory Approval for Its Nano-Cancer® Therapy

Abstract:
Following two decades of intensive research and development efforts, MagForce Nanotechnologies AG, a Berlin-based medical technology company founded in 1997, has received European regulatory approval for its Nano-Cancer® therapy.

MagForce Nanotechnologies AG Receives European Regulatory Approval for Its Nano-Cancer® Therapy

Berlin | Posted on June 28th, 2010

official notice of regulatory approval signifies that the authorized testing centers in Germany responsible for conformity evaluation of medical devices have completed their examination of the application submitted for market approval of Nano-Cancer® therapy and that the approved medical devices fulfill all requirements with regard to quality, safety and medical efficacy.

"This is a historic milestone for MagForce," exclaimed Dr. Peter Heinrich, CEO of MagForce Nanotechnologies AG, on news of the regulatory approval. "Over the past twenty years, the company has worked in close partnership with a number of partners in academia, particularly the Charité University Medical Center in Berlin, to develop this highly innovative therapeutic approach for treating solid tumors. Along this long road, Dr. Andreas Jordan, founder of the company and my colleague on the executive board, always remained true to his vision of an entirely new concept in cancer treatment based on recent advances in nanotechnology. In recognition of his many years of dedication, I am thus particularly delighted that, with regulatory approval received, a revolutionary new product in nanomedicine may now be brought to market."

The regulatory approval covers the treatment of brain tumors throughout the European Union. With this approval in hand, the company is now accelerating and strengthening its sales and marketing activities to introduce its new therapeutic procedure into the major European markets, starting with Germany, as well as moving its business model into the next stage. A further focus of these activities in preparation for market launch is discussion with medical insurers, such as the German Krankenkassen, regarding coverage for this therapy. In addition, MagForce will in the coming months be defining a development, partnership and commercialization strategy for the North American and Asian markets.

Initial revenues from the commercialization of Nano-Cancer® therapy through the company's own sales structures should be reflected in its 2011 financial results. With European regulatory approval now received, the company anticipates that its share listing on the Frankfurt Stock Exchange will be changed over the medium term from the Entry Standard segment to Prime Standard.

Disclaimer:

This release may contain forward-looking statements and information which may be identified by formulations using terms such as "expects", "aims", "anticipates", "intends", "plans", "believes", "seeks", "estimates" or "will". Such forward-looking statements are based on our current expectations and certain assumptions which may be subject to variety of risks and uncertainties. The results actually achieved by MagForce Nanotechnologies AG may substantially differ from these forward-looking statements. MagForce Nanotechnologies AG assumes no obligation to update these forward-looking statements or to correct them in case of developments which differ from those anticipated.

####

About MagForce Nanotechnologies AG
MagForce Nanotechnologies AG is a world-leading company in the area of nanotechnology-based cancer treatment. The proprietary procedure which it has developed, Nano-Cancer® therapy, enables the targeted treatment of solid tumors through the intratumoral release of heat from magnetic nanoparticles. Its products used in the therapy, NanoTherm® and NanoActivator®, have received EU-wide regulatory approval as medical devices for the treatment of brain tumors.

For more information, please click here

Contacts:
MagForce Nanotechnologies AG
Christofer Radic
Public Relations Manager
phone: +49 (0)30 308 380 31
fax: +49 (0)30 308 380 99

Copyright © MagForce Nanotechnologies AG

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

A nanoscale wireless communication system via plasmonic antennas: Greater control affords 'in-plane' transmission of waves at or near visible light August 27th, 2016

Forces of nature: Interview with microscopy innovators Gerd Binnig and Christoph Gerber August 26th, 2016

A promising route to the scalable production of highly crystalline graphene films August 26th, 2016

Graphene under pressure August 26th, 2016

Govt.-Legislation/Regulation/Funding/Policy

Analog DNA circuit does math in a test tube: DNA computers could one day be programmed to diagnose and treat disease August 25th, 2016

New approach to determining how atoms are arranged in materials August 25th, 2016

Johns Hopkins scientists track metabolic pathways to find drug combination for pancreatic cancer August 25th, 2016

New electrical energy storage material shows its power: Nanomaterial combines attributes of both batteries and supercapacitors August 25th, 2016

Nanomedicine

Nanofiber scaffolds demonstrate new features in the behavior of stem and cancer cells August 25th, 2016

Johns Hopkins scientists track metabolic pathways to find drug combination for pancreatic cancer August 25th, 2016

50 years after the release of the film 'Fantastic Voyage,' science upstages fiction: Science upstages fiction with nanorobotic agents designed to travel in the human body to treat cancer August 25th, 2016

Tunneling nanotubes between neurons enable the spread of Parkinson's disease via lysosomes August 24th, 2016

Announcements

A nanoscale wireless communication system via plasmonic antennas: Greater control affords 'in-plane' transmission of waves at or near visible light August 27th, 2016

Forces of nature: Interview with microscopy innovators Gerd Binnig and Christoph Gerber August 26th, 2016

A promising route to the scalable production of highly crystalline graphene films August 26th, 2016

Graphene under pressure August 26th, 2016

Financial Reports

Nanometrics Reports Second Quarter 2016 Financial Results July 26th, 2016

Nanobiotix revenue for Q2 2016 July 14th, 2016

Nanometrics to Announce Second Quarter Financial Results on July 26, 2016 July 6th, 2016

Nanometrics to Announce First Quarter Financial Results on April 26, 2016 April 5th, 2016

Nanobiotechnology

Analog DNA circuit does math in a test tube: DNA computers could one day be programmed to diagnose and treat disease August 25th, 2016

Nanofiber scaffolds demonstrate new features in the behavior of stem and cancer cells August 25th, 2016

Johns Hopkins scientists track metabolic pathways to find drug combination for pancreatic cancer August 25th, 2016

50 years after the release of the film 'Fantastic Voyage,' science upstages fiction: Science upstages fiction with nanorobotic agents designed to travel in the human body to treat cancer August 25th, 2016

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







Car Brands
Buy website traffic